Intellia Therapeutics Inc Stock News

CAMBRIDGE, Mass., April 28, 2020 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, BidAskClub reports. Other research ana

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday, Zacks.com reports. The firm currently has

After Piper Sandler and RBC Capital gave Exelixis (NASDAQ: EXEL) a Buy rating last month, the company received another Buy, this time from Oppenheimer.

After Piper Sandler and RBC Capital gave Exelixis (NASDAQ: EXEL) a Buy rating last month, the company received another Buy,

Oppenheimer analyst Silvan Tuerkcan maintained a Buy rating on Seattle Genetics (SGEN) yesterday and set a price target of $146.00. The company's shares

Oppenheimer analyst Silvan Tuerkcan maintained a Buy rating on Seattle Genetics (SGEN – Research Report) yesterday and set a price

Bank of New York Mellon Corp increased its holdings in Intellia Therapeutics Inc (NASDAQ:NTLA) by 4.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 223,967

A Relative Strength Rating upgrade for Intellia Therapeutics shows improving technical performance. Will it continue?

Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) have been assigned an average recommendation of “Buy” from the ten brokerages that are currently covering the stock, MarketBeat Ratings reports. F

Exchange Traded Concepts LLC raised its position in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 98.8% during the first quarter, according to its most recent disclosure with the Securities & E

If you own shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) then it's worth thinking about how it contributes to...

UBS Asset Management Americas Inc. lessened its position in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 4.1% in the fourth quarter, according to the company in its most recent disclosure with

Intellia Therapeutics (NASDAQ:NTLA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, Zacks.com reports. Ac

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The brokerage cur